Disc Medicine Probed for Fraud After 22% Stock Plunge

Edgen Stock

·Mar 23 2026, 20:07

Share to

Share to

Copy link

Key Takeaways

Disc Medicine (NASDAQ: IRON) is facing a securities fraud investigation following a significant stock drop earlier in the year. The legal action centers on allegations that the company may have provided misleading information to investors prior to a major regulatory setback.

FDA Rejection: The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter on February 13, 2026, declining to approve Disc Medicine's New Drug Application for bitopertin.
Market Collapse: Following the FDA's decision, the company's stock price collapsed by 22% on February 13, 2026, causing significant losses for shareholders.
Legal Fallout: Rosen Law Firm announced on March 23, 2026, that it is formally investigating the company for issuing potentially misleading business information, paving the way for a class-action lawsuit.

Stock Plummets 22% After FDA Rejects Key Drug

Disc Medicine's stock value was severely impacted on February 13, 2026, when its shares fell 22% in a single day. The sharp decline was a direct result of the U.S. Food and Drug Administration (FDA) issuing a Complete Response Letter (CRL) regarding the company's bitopertin program. A CRL indicates that the agency cannot approve the New Drug Application (NDA) in its current form, citing uncertainties that require additional evidence from the company. This regulatory setback effectively halts the drug's path to market and casts serious doubt on its future revenue potential, triggering an immediate and negative investor reaction.

Rosen Law Firm Launches Fraud Investigation on March 23

Building on the fallout from the FDA's decision, Rosen Law Firm announced on March 23, 2026, that it has launched an investigation into potential securities fraud on behalf of Disc Medicine shareholders. The probe centers on allegations that the company may have issued materially misleading business information to the public leading up to the regulatory rejection. By pursuing this action, the law firm is preparing a potential class-action lawsuit that seeks to recover losses for investors who purchased securities before the 22% stock price collapse. The investigation formalizes the legal risks for Disc Medicine, adding potential litigation costs and penalties to the company's existing clinical challenges.